29/10/2024
On Thursday 24th October Mikrobiomik celebrated its first INVESTOR’S DAY, a unique meeting, where the progress and milestones of the promising projects and the future growth plan were shared.
The event took place at the Hotel NH Collection Villa de Bilbao, was an exceptional day with a stellar program that included the participation of the most renowned professionals from different fields as well as prominent entrepreneurs from the pharmaceutical and biotechnology sector, partners and investors. The first block dedicated to the clinic was opened by Dr. Rosa del Campo, a pioneer in the study of the intestinal microbiota at a national and European level, who presented the next therapeutic challenges of the microbiota. Dr. Elena Bereciartua (Infectious Diseases Service, Cruces University Hospital) presented the results of the ICD-01 clinical trial to treat Clostridioides Difficile infections.
One of the highlights of the morning took place when Axel Sommer shared the experience of his father’s recovery due to the supply of the biological drug under investigation, MKB-01, through the compassionate use program, whereby patients infected with this bacterium are treated with MBK-01 completely free of charge.
Touching words from Axel, telling the story of his father, who was hospitalized in Gorliz Hospital with a very complex health diagnosis, including a recurrent episode of Clostridioides Difficile, and who, after taking the 4 capsules of MBK-01, was able to cure the severe episodes of diarrhea, and so improve his medical condition and quality of life. Following this touching story,
Dr. María Varela, from La Paz Hospital told the case of another ALS (amyotrophic lateral sclerosis) patient successfully treated with MKB-01, who eradicated the recurrent episodes of diahrrea in only 48 hours.
The second segment, led by the CEO and Co-founder of the company Dr. Juan Basterra, reviewed the 6 years since the foundation of Mikrobiomik in 2018, the challenges overcome, and the milestones achieved. He announced the authorization by the AEMPS (Spanish Agency for Medicines and Health Products) of a Phase IIa clinical trial in patients with recurrent diverticulitis, in collaboration with the Ramón y Cajal Institute for Health Research (IRYCIS). Then, the Director of Business Development and Innovation, Dr. Patricia del Río, presented the powerful reasons to trust and invest in Mikrobiomik, which seeks to raise 5 million euros, aimed to build a new production facility to bring its drug to market and advance in the clinical trials we have already ongoing, as well as the creation of new jobs by attracting talent and, obviously, to launch MBK-01 centrally and thus reach the entire EU market in 2027. Caixa Bank, responsible for managing the investment round, through Antonio San Segundo, explained the terms of this Series A investment round.
The day ended with the participation of Olatz Goitia, General Director of Beaz, Marta Martinez, Director of business transformation of Cebek, the Business Confederation of Bizkaia, and the closing speech was given by Oscar Ugarte, General Director of Seed Capital Bizkaia, an institution of the Basque Government that has supported Mikrobiomik with its various grants at different stages, from its initial entrepreneurial stage to its current industrialization project.
An exceptional day, an opportunity to review the short but intense path that has been achieved at Mikrobiomik. This event marked a milestone on the company’s path towards becoming a European benchmark in microbiota research.
